Levitra, UroXatral QT prolongation
Executive Summary
QT prolongation associated with Bayer/GlaxoSmithKline's erectile dysfunction therapy Levitra and Sanofi-Synthelabo's benign prostatic hyperplasia agent UroXatral will be discussed by FDA's Cardiovascular & Renal Drugs Advisory Committee on May 29. Levitra (vardenafil) has been "approvable" at FDA since July 2002 and was recently approved in Europe ("The Pink Sheet" March 17, p. 6). UroXatral has been "approvable" at FDA since October 2001 [To watch a webcast or video of this meeting, go to FDAadvisoryCommittee.com]...
You may also be interested in...
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.